SALT LAKE CITY , March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024 . Full Year 2024 Financial Results: Revenue of $3.9 million , which declined from $6.8 million during the prior year primarily due... Read More

SALT LAKE CITY , March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2024 results on Thursday, March 27, 2025 , after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to... Read More

The symposium exploring advances in cancer prevention and care is set to take place on March 4 , International HPV Awareness Day, in Baroda, India SALT LAKE CITY , March 3, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company and CoSara... Read More

The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a test component SALT LAKE CITY , Feb. 21, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, following a collaborative and informative dialogue with... Read More

SALT LAKE CITY , Jan. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced that it will be hosting a booth at BioUtah's Life Sciences Day on the Hill today at the Utah State Capitol Rotunda. The Life Sciences Day on the Hill is presented by the Utah Life Sciences... Read More

SALT LAKE CITY , Jan. 7, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be participating in Nasdaq's Live from MarketSite broadcast at the Silicon Slopes Summit 2025 on January 14, 2025 . Live from MarketSite is Nasdaq's flagship broadcast... Read More

New oligonucleotide facility is designed to support "Make in India " initiative by synthesizing Co-Primers ® in-house. Attendees of new ribbon-cutting event expected to include representatives from NGOs and government leaders SALT LAKE CITY , Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of... Read More

SALT LAKE CITY , Nov. 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2024 . Third Quarter 2024 Financial Results: Revenue of $0.6 million , which declined from $2.5 million during the prior year primarily due to timing of grant... Read More

SALT LAKE CITY , Nov. 5, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth and delivering a presentation at the MEDICA 2024 trade fair in Düsseldorf, Germany on November 11-14 . MEDICA has become the largest medical B2B trade... Read More

SALT LAKE CITY , Oct. 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2024 results on Thursday, November 7, 2024 , after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its... Read More

SALT LAKE CITY , Oct. 21, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be hosting a booth at Africa Health/Medlab Africa in Cape Town, South Africa on October 22-24, 2024 . The conference website describes it as the largest... Read More

SALT LAKE CITY , Oct. 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be hosting a booth at the Utah Health Care Association/Utah Center for Assisted Living (UHCA/UCAL) Convention & Expo at the Mountain America Expo Center in... Read More

SALT LAKE CITY , Sept. 24, 2024 /PRNewswire/ -- Co-Diagnostics, Inc . (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced Company representatives will be accompanying Utah Governor Cox and the Governor's Office of Economic Opportunity, as part of the latest World Trade Center (WTC) Utah trade mission to South... Read More

SALT LAKE CITY , Sept. 5, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has performed an in silico analysis of the Co-Dx™ Logix Smart® Mpox (2-Gene) RUO test to evaluate the possible impact of clade Ib mpox on the test. The results of the analysis... Read More

SALT LAKE CITY , Aug. 15, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hosting a booth at the 16 th Annual Next Generation Dx Summit, held virtually and in-person in Washington, D.C. on August 19-21, 2024 . Cambridge... Read More

SALT LAKE CITY , August 8, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2024 . Second Quarter 2024 Financial Results: Revenue of $2.7 million , up from $0.2 million during the prior year primarily due to the achievement of certain... Read More

SALT LAKE CITY , July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at the Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting and expo held July 28-August 1, 2024 , in Chicago, IL. Co-Dx will also be... Read More

SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2024 results on Thursday, August 8, 2024 , after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its... Read More

SALT LAKE CITY , July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that use of the Company's vector control technology will expand to the 15 th U.S. state following an installation in Nevada next week. Co-Dx vector control technology includes Vector... Read More

SALT LAKE CITY , June 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida , on June 19-21 . FIME is described as the Americas' leading medical... Read More

The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY , June 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today... Read More

SALT LAKE CITY , May 9, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Dx," or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Results: Revenue of $0.5 million , down from $0.6 million during the prior year. Grant revenue... Read More

SALT LAKE CITY , April 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2024 financial results on Thursday, May 9, 2024 , after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its... Read More

SALT LAKE CITY , April 24, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth and delivering a presentation at the 9 th Asia Pacific Region Conference (APRC) of the International Union Against Tuberculosis and Lung... Read More

Ribbon-cutting included support from Mayor Wood of South Salt Lake and other dignitaries SALT LAKE CITY , April 12, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today... Read More

SALT LAKE CITY , April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations... Read More

Presentation included announcement of the opening of the new manufacturing facility in Salt Lake City, UT SALT LAKE CITY , March 21, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that in his keynote address at the 5 th Annual MarketsandMarkets conference in... Read More

SALT LAKE CITY, Utah , March 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Dx CEO Dwight Egan will deliver the keynote address at the 5 th Annual Infectious Disease Diagnostics and Molecular Diagnostics Conference, organized by MarketsandMarkets... Read More

SALT LAKE CITY , March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023 . Full Year 2023 Financial Results: Revenue of $6.8 million , down from $34.2 million during the prior year primarily due to the decline in global... Read More

The clinical laboratory real-time PCR multiplex test was designed using Co-Dx Co-Primers™ and licensed by the CDSCO for use in diagnostic procedures SALT LAKE CITY , March 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd... Read More

SALT LAKE CITY , Feb. 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2023 financial results on Thursday, March 14, 2024 , after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.... Read More

SALT LAKE CITY , Feb. 1, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the list of events it has chosen to exhibit at or participate in during February, 2024, and which strategically align with the Company's vision. At each event, Co-Dx will discuss its... Read More

SALT LAKE CITY , Jan. 3, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth next week at the 2024 Consumer Electronics Show (CES) from January 9-12 in Las Vegas, Nevada . The Company will be exhibiting its upcoming Co-Dx™ PCR... Read More

The Company's Emergency Use Authorization submission is for the new Co-Dx PCR Pro instrument and COVID-19 test kit, designed for point-of-care and at-home. The menu of tests in development for the platform includes TB, HPV, and a multiplex respiratory panel for flu A/B, COVID-19, and RSV SALT LAKE CITY , Dec. 27, 2023 /PRNewswire/ -- Co-Diagnostics , Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics... Read More

SALT LAKE CITY , Nov. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the Piper Sandler 35 th Annual Healthcare Conference in New York City , New York on November 30, 2023 . The presentation will be conducted... Read More

Receives grant award from the Bill & Melinda Gates Foundation in the amount of $9.0M for the development of tuberculosis test on Co-Dx™ PCR platform. SALT LAKE CITY , Nov. 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2023.... Read More

Company to use funds awarded by the Bill & Melinda Gates Foundation toward the tuberculosis test for its Co-Dx™ PCR platform SALT LAKE CITY , Nov. 2, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced a grant awarded by the Bill & Melinda Gates Foundation to... Read More

SALT LAKE CITY , Oct. 31, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the list of events it has chosen to exhibit at or attend during November, 2023, which strategically align with its mission of increasing accessibility of affordable gold-standard PCR... Read More

SALT LAKE CITY , Oct. 26, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2023 results on Thursday, November 9, 2023 , after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its... Read More

SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth this week at the Caribbean Association of Medical Technologies (CASMET) Scientific Symposium and BGM, held in Barbados October 22-26, 2023.... Read More

SALT LAKE CITY , Oct. 16, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth this week at Africa Health/Medlab Africa in Johannesburg, South Africa on October 17-19, 2023 . The conference is described as the largest... Read More

SALT LAKE CITY , Sept. 27, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be sponsoring and participating in the Utah Health Care Association/Utah Center for Assisted Living Convention (UHCA/UCAL) & Expo at the Mountain America... Read More

SALT LAKE CITY , Sept. 22, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be hosting a booth and presenting at the 6 th Advances in Circulating Tumor Cells ("ACTC") conference held this week in Skiathos, Greece . This year's... Read More

SALT LAKE CITY , Sept. 21, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the Gilmartin Group Annual Emerging Growth Showcase. Dwight Egan , Company CEO, will be participating in a fireside chat discussing Company... Read More

SALT LAKE CITY , Sept. 7, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the H.C. Wainwright & Co. 25 th Annual Global Investment Conference, being held virtually and in-person on September 11-13 in New York City... Read More

SALT LAKE CITY , Aug. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Ivory Chang as the Company's Chief Regulatory Affairs Officer. Ms. Chang's in-depth regulatory affairs experience has included time spent with several... Read More

SALT LAKE CITY , Aug. 18, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hosting a booth at the 15 th Annual Next Generation Dx Summit, held virtually and in-person in Washington, D.C. on August 21-23, 2023 . The Next... Read More

SALT LAKE CITY , Aug. 16, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth this week at Asia Health/Medlab Asia 2023 from August 16-18 at the IMPACT Exhibition Center in Bangkok, Thailand . The Asia Health/Medlab... Read More

Co-Dx receives grant awards from the Bill & Melinda Gates Foundation; NIH RADx® Tech to develop tests on our new Co-Dx PCR Home™ platform SALT LAKE CITY , Aug. 10, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the quarter ended June 30, 2023 . Second Quarter... Read More

SALT LAKE CITY , July 27, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2023 results on Thursday, August 10, 2023 , after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its... Read More

SALT LAKE CITY , July 20, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at the American Association for Clinical Chemistry (AACC) annual meeting and expo held July 23-27, 2023 in Anaheim, CA. Co-Dx will also be holding a special... Read More

The Company intends to use funds awarded by the Bill & Melinda Gates Foundation toward completion of tuberculosis and HPV tests for its Co-Dx PCR Home™ platform SALT LAKE CITY , July 18, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced grants awarded by the... Read More

The Company intends to use the funds awarded by the National Institutes of Health for completion of its upper respiratory panel multiplex on Co-Dx PCR Home™ platform SALT LAKE CITY , July 13, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has been... Read More

Clinical trials for Co-Dx PCR Home™ platform remain on track; Solid cash position and grant funding support long-term strategy SALT LAKE CITY , May 11, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the quarter ended March 31, 2023. First Quarter 2023 Financial... Read More

SALT LAKE CITY , May 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at Argentum's 2023 Senior Living Executive Conference and Expo, being held May 8-10 in New Orleans, LA . The conference is the official meeting of Argentum, the... Read More

SALT LAKE CITY , May 5, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2023 results on Thursday, May 11, 2023 , after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial... Read More

SALT LAKE CITY , April 26, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the Caribbean Public Health Agency (CARPHA) 67 th Annual Health Research Conference, being held in-person April 27-29, 2023 , in the Bahamas . The... Read More

SALT LAKE CITY , April 13, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) April 15-18, 2023 , in Copenhagen, Denmark . ECCMID is described... Read More

SALT LAKE CITY , March 21, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company CEO will deliver the keynote address at the 4 th Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference, held March 23-24, 2023 ,... Read More

Chair of Company's SAB, Dr. Carl Wittwer , to present on at-home PCR testing SALT LAKE CITY , March 17, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 10 th Gene Quantification Event held March 20-24 at the Technical... Read More

Full-year Results Impacted by Lower Demand for COVID-19 Testing Announced Initiation of Clinical Evaluations for Co-Dx PCR Home™ Platform SALT LAKE CITY , March 16, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the full year ended December 31, 2022 . Full Year... Read More

SALT LAKE CITY , March 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2022 results on Thursday, March 16, 2023 , after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. EDT to... Read More

SALT LAKE CITY , March 2, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 30 th Molecular and Precision Med TRI-CON ("TRI-CON"), held virtually and in person March 6-8, 2023 , in San Diego, CA. Co-Dx, which is also one... Read More

SALT LAKE CITY , Feb. 28, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming 89 th annual American Mosquito Control Association (AMCA) conference on February 28-March 3 in Reno, Nevada . The AMCA Annual Meeting is listed as... Read More

SALT LAKE CITY , Feb. 22, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has commenced clinical evaluations for its at-home and point-of-care Co-Dx... Read More

SALT LAKE CITY , Feb. 2, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming Medlab Middle East 2023 trade show held February 6-9 at the Dubai World Trade Centre. It is expected that the 22 nd edition of the conference will... Read More

Designed using the Company's proprietary platform, initial test design remains effective detection tool even after three years of variants and more than 33 million sold worldwide; Company also announces participation in Life Sciences Day on the Hill on Jan 27 SALT LAKE CITY , Jan. 24, 2023 /PRNewswire/ -- Co-Diagnostics, Inc.... Read More

SALT LAKE CITY , Jan. 5, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth this week at the 2023 Consumer Electronics Show (CES) this year from January 5-8 in Las Vegas, Nevada . The Company will be exhibiting its upcoming... Read More

SALT LAKE CITY , Nov. 30, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting on December 1, 2022 , at the Piper Sandler 34 th Annual Healthcare Conference, held November 29-December 31, 2022 , in New York City , New York... Read More